{"id":"bisaramil","rwe":[{"pmid":"30594781","year":"2019","title":"The antiarrhythmic actions of bisaramil and penticainide result from mixed cardiac ion channel blockade.","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"},{"pmid":"10461773","year":"1999","title":"Chronotropic, inotropic, dromotropic and coronary vasodilator effects of bisaramil, a new class I antiarrhythmic drug, assessed using canine isolated, blood-perfused heart preparations.","finding":"","journal":"Japanese journal of pharmacology","studyType":"Clinical Study"},{"pmid":"9544797","year":"1998","title":"Effects of bisaramil, a novel class I antiarrhythmic agent, on heart, skeletal muscle and brain Na+ channels.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"9264043","year":"1997","title":"Bisaramil and antiarrhythmics as inhibitors of free radical generation.","finding":"","journal":"Pharmacological research","studyType":"Clinical Study"},{"pmid":"9408384","year":"1997","title":"Cardioprotection during heart ischemia-reperfusion.","finding":"","journal":"Acta chirurgica Hungarica","studyType":"Clinical Study"}],"tags":[{"label":"bisaramil","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"alpha-yutac","offLabel":[],"synonyms":["bisaramil","alpha-Yutac"],"timeline":[],"brandName":"Alpha-Yutac","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"bisaramil","explanation":"Imagine your body's cells have locks on them, and each lock has a unique key. Alpha-Yutac is like a key that fits into one of these locks, but we don't know which lock it is or what it does when it's inside. This binding action is thought to affect the way cells work, but the details are still unclear.","oneSentence":"Alpha-Yutac works by binding to a specific target, but the exact mechanism is not well understood.","technicalDetail":"Alpha-Yutac is a small molecule that binds to a specific target, likely a protein or receptor, to exert its therapeutic effects. The exact nature of this interaction is unknown, but it is thought to be reversible and may involve changes in cellular signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/377","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BISARAMIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BISARAMIL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:00:41.177181","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:51:23.016513+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"bisaramil","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03010761","phase":"PHASE2","title":"Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer","status":"TERMINATED","sponsor":"China Medical University Hospital","startDate":"2016-01-14","conditions":["Addiction"],"enrollment":90,"completionDate":"2018-01-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"FVT2ESG270","CHEBI":"CHEBI:135371","INN_ID":"6326","UMLSCUI":"C0106533","ChEMBL_ID":"CHEMBL4297144","PUBCHEM_CID":"3033742","MESH_SUPPLEMENTAL_RECORD_UI":"C045644"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"8.6 hours","clearance":"17.0 mL/min/kg","volumeOfDistribution":"9.0 L/kg"},"publicationCount":19,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2019 Mar","pmid":"30594781","title":"The antiarrhythmic actions of bisaramil and penticainide result from mixed cardiac ion channel blockade.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"1999 Jul","pmid":"10461773","title":"Chronotropic, inotropic, dromotropic and coronary vasodilator effects of bisaramil, a new class I antiarrhythmic drug, assessed using canine isolated, blood-perfused heart preparations.","journal":"Japanese journal of pharmacology"},{"date":"1998 Jan 19","pmid":"9544797","title":"Effects of bisaramil, a novel class I antiarrhythmic agent, on heart, skeletal muscle and brain Na+ channels.","journal":"European journal of pharmacology"},{"date":"1997 Apr","pmid":"9264043","title":"Bisaramil and antiarrhythmics as inhibitors of free radical generation.","journal":"Pharmacological research"},{"date":"1997","pmid":"9408384","title":"Cardioprotection during heart ischemia-reperfusion.","journal":"Acta chirurgica Hungarica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alpha-Yutac (BISARAMIL) is a small molecule drug in the bisaramil class, but details about its target and approved indications are unknown. Its commercial status, including patent status and generic availability, is also unclear. The half-life of Alpha-Yutac is approximately 8.6 hours, but its bioavailability is unknown. Further information about this drug is limited. As a result, its clinical use and safety profile are not well established.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:51:23.016513+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}